Home > Epitomee Medical to Present Clinical Data Demonstrating Weight Loss in Women Aged 50 and Older at ObesityWeek 2026

Latest news

Epitomee Medical to Present Clinical Data Demonstrating Weight Loss in Women Aged 50 and Older at ObesityWeek 2026

Epitomee® Capsule led to 7.6% average weight loss in women aged 50 and older, with 29% losing at least 10% bodyweight in 24 weeks

CAESAREA, Israel – November 11, 2026 – Epitomee Medical Ltd. (TASE: EPIT), a company focused on commercializing an innovative weight management medical device and developing a biologic drug-delivery platform, today announced that clinical data from the RESET study evaluating the Epitomee® Capsule for weight loss in women aged 50 and older will be presented in a poster session at ObesityWeek® 2026, the Obesity Society’s 44th Annual Meeting, taking place November 14–17, 2026, in Washington, DC.

The post hoc analysis, also published in Diabetes Technology and Obesity Medicine (DOI: 10.1177/29986702251408809), included 104 women aged ≥50, randomized to either Epitomee® Capsule (n = 52) or placebo (n = 52), and both groups received the same lifestyle intervention.

At 24 weeks, 29% of the Epitomee® group lost at least 10% bodyweight, compared to 9% of the placebo group; in addition, 56% of the Epitomee® group moved to a lower BMI category, compared to 21% of the placebo group. Adverse event rates were similar, and no serious adverse events were reported in either subgroup.

“We are pleased to participate in the Obesity Society’s Annual Meeting to continue engaging with the broader weight management community,” said Dolev Rafaeli, Chief Executive Officer of Epitomee Medical. “ObesityWeek presents a prime opportunity to highlight the innovation, ease of use, and remarkable weight loss results achieved with the Epitomee® Capsule. Weight gain during and after menopause is a major women’s health challenge, increasing cardiometabolic risk while becoming harder to manage due to hormonal and metabolic changes. In the United States, we have recently launched our direct-to-consumer platform, accompanied by a digital health campaign, to reach people interested in the Epitomee® Capsule as a non-drug alternative to GLP-1 weight management medications.”

Presentation Details

  • Title: A Novel Approach to Weight Loss in Women Over 50 Years: Insights From RESET Study With a Shape-Shifting Hydrogel Capsule
  • Session: Poster Session 3, Women’s Health, Pregnancy & Reproductive-Metabolic Outcomes (Poster 798)
  • Presenter: Gitanjali Srivastava, MD, MEng, Professor of Medicine and Founding Director of Obesity Medicine Fellowship, Vanderbilt University Medical Center
  • Presentation date and time: Monday, November 16, 2:30 pm ET
  • Location: Exhibit Hall BCD, Gaylord National Resort & Convention Center, 201 Waterfront St., National Harbor, MD 20745

About Epitomee Medical

Epitomee Medical Ltd. is a pioneering technology-based health solutions company, committed to advancing innovative therapies. The company is advancing two major fields: weight management and biologic drug delivery. In addition to its flagship weight management solution, Epitomee Medical is developing a cutting-edge platform focused on the oral delivery of biologics. This innovative platform is designed to transport drugs to the absorption site with enhanced bioavailability.

Contacts

Investor Relations
Moran Meir-Beres
LifeSci Advisors
moran@lifesciadvisors.com

Media
Dikla Ivri
Ivri PR
dikla@ivripr.com